scholarly journals Progression from islet autoimmunity to clinical type 1 diabetes is influenced by genetic factors: results from the prospective TEDDY study

2018 ◽  
Vol 56 (9) ◽  
pp. 602-605 ◽  
Author(s):  
Andreas Beyerlein ◽  
Ezio Bonifacio ◽  
Kendra Vehik ◽  
Markus Hippich ◽  
Christiane Winkler ◽  
...  

BackgroundProgression time from islet autoimmunity to clinical type 1 diabetes is highly variable and the extent that genetic factors contribute is unknown.MethodsIn 341 islet autoantibody-positive children with the human leucocyte antigen (HLA) DR3/DR4-DQ8 or the HLA DR4-DQ8/DR4-DQ8 genotype from the prospective TEDDY (The Environmental Determinants of Diabetes in the Young) study, we investigated whether a genetic risk score that had previously been shown to predict islet autoimmunity is also associated with disease progression.ResultsIslet autoantibody-positive children with a genetic risk score in the lowest quartile had a slower progression from single to multiple autoantibodies (p=0.018), from single autoantibodies to diabetes (p=0.004), and by trend from multiple islet autoantibodies to diabetes (p=0.06). In a Cox proportional hazards analysis, faster progression was associated with an increased genetic risk score independently of HLA genotype (HR for progression from multiple autoantibodies to type 1 diabetes, 1.27, 95% CI 1.02 to 1.58 per unit increase), an earlier age of islet autoantibody development (HR, 0.68, 95% CI 0.58 to 0.81 per year increase in age) and female sex (HR, 1.94, 95% CI 1.28 to 2.93).ConclusionsGenetic risk scores may be used to identify islet autoantibody-positive children with high-risk HLA genotypes who have a slow rate of progression to subsequent stages of autoimmunity and type 1 diabetes.

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 243-OR
Author(s):  
LAURIC A. FERRAT ◽  
ANDREA STECK ◽  
HEMANG M. PARIKH ◽  
LU YOU ◽  
SUNA ONENGUT-GUMUSCU ◽  
...  

Diabetes Care ◽  
2018 ◽  
Vol 41 (9) ◽  
pp. 1887-1894 ◽  
Author(s):  
Maria J. Redondo ◽  
Susan Geyer ◽  
Andrea K. Steck ◽  
Seth Sharp ◽  
John M. Wentworth ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1535-P
Author(s):  
RACHEL G. MILLER ◽  
TINA COSTACOU ◽  
SUNA ONENGUT-GUMUSCU ◽  
WEI-MIN CHEN ◽  
STEPHEN S. RICH ◽  
...  

Author(s):  
German Tapia ◽  
Tommi Suvitaival ◽  
Linda Ahonen ◽  
Nicolai A Lund-Blix ◽  
Pål R Njølstad ◽  
...  

Abstract Background and aim Genetic markers are established as predictive of type 1 diabetes, but unknown early life environment is believed to be involved. Umbilical cord blood may reflect perinatal metabolism and exposures. We studied whether selected polar metabolites in cord blood contribute to prediction of type 1 diabetes. Methods Using a targeted UHPLC-QQQ-MS platform, we quantified 27 low molecular weight metabolites (including amino acids, small organic acids and bile acids) in 166 children, who later developed type 1 diabetes, and 177 random control children in the Norwegian Mother, Father and Child (MoBa) cohort. We analysed the data using logistic regression (estimating odds ratios per standard deviation [aOR]), area under the receiver operating characteristic curve (AUC) and k-means clustering. Metabolites were compared to a genetic risk score based on 51 established non-HLA SNPs, and a four-category HLA risk group. Results The strongest associations for metabolites were aminoadipic acid (aOR=1.23,95%CI:0.97–1.55), indoxyl sulfate (aOR=1.15,95%CI:0.87–1.51), and tryptophan (aOR=0.84,95%CI:0.65–1.10), with other aORs close to 1.0, and none significantly associated with type 1 diabetes. K-means clustering identified six clusters, none of which were associated with type 1 diabetes. Cross-validated AUC showed no predictive value of metabolites (AUC 0.49), while the non-HLA genetic risk score AUC was 0.56 and the HLA risk group AUC was 0.78. Conclusions In this large study, we found no support of a predictive role of cord blood concentrations of selected bile acids and other small polar metabolites in the development of type 1 diabetes.


2019 ◽  
Vol 36 (12) ◽  
pp. 1694-1702 ◽  
Author(s):  
H. Yaghootkar ◽  
F. Abbasi ◽  
N. Ghaemi ◽  
A. Rabbani ◽  
M. N. Wakeling ◽  
...  

2020 ◽  
Vol 58 (4) ◽  
pp. e102-e104 ◽  
Author(s):  
Jonathan M. Locke ◽  
Mark J. Latten ◽  
Renu Y. Datta ◽  
Andrew R. Wood ◽  
Martin A. Crockard ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Caroline A. Brorsson ◽  
Lotte B. Nielsen ◽  
Marie Louise Andersen ◽  
Simranjeet Kaur ◽  
Regine Bergholdt ◽  
...  

Genome-wide association studies (GWAS) have identified over 40 type 1 diabetes risk loci. The clinical impact of these loci onβ-cell function during disease progression is unknown. We aimed at testing whether a genetic risk score could predict glycemic control and residualβ-cell function in type 1 diabetes (T1D). As gene expression may represent an intermediate phenotype between genetic variation and disease, we hypothesized that genes within T1D loci which are expressed in islets and transcriptionally regulated by proinflammatory cytokines would be the best predictors of disease progression. Two-thirds of 46 GWAS candidate genes examined were expressed in human islets, and 11 of these significantly changed expression levels following exposure to proinflammatory cytokines (IL-1β+ IFNγ+ TNFα) for 48 h. Using the GWAS single nucleotide polymorphisms (SNPs) from each locus, we constructed a genetic risk score based on the cumulative number of risk alleles carried in children with newly diagnosed T1D. With each additional risk allele carried, HbA1c levels increased significantly within first year after diagnosis. Network and gene ontology (GO) analyses revealed that several of the 11 candidate genes have overlapping biological functions and interact in a common network. Our results may help predict disease progression in newly diagnosed children with T1D which can be exploited for optimizing treatment.


Diabetes Care ◽  
2019 ◽  
Vol 42 (3) ◽  
pp. 406-415 ◽  
Author(s):  
Suna Onengut-Gumuscu ◽  
Wei-Min Chen ◽  
Catherine C. Robertson ◽  
Jessica K. Bonnie ◽  
Emily Farber ◽  
...  

Diabetes Care ◽  
2019 ◽  
Vol 42 (2) ◽  
pp. 200-207 ◽  
Author(s):  
Seth A. Sharp ◽  
Stephen S. Rich ◽  
Andrew R. Wood ◽  
Samuel E. Jones ◽  
Robin N. Beaumont ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1715-P
Author(s):  
SHYLAJA SRINIVASAN ◽  
AARON LEONG ◽  
MIRIAM UDLER ◽  
BIANCA C. PORNEALA ◽  
JAMES B. MEIGS ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document